Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
Issues related to down coding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs).
Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act.
of2023 or the PATIENT Act of 2023.
Advocating for access to biosimilars.
HR 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act.
S. 652/HR 2630, Safe Step Act.
S. 1375/HR 830, HELP Copays Act.
Issues related to White Bagging.
Access to Alzheimer's Disease therapies.
None
Duration: August 31, 2021
to
present
General Issues: Medicare/Medicaid , Health Issues
Spending: about $297,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2021: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Medicare Payment Advisory Commission (MedPAC)
Affiliated organizations: IVX Health; Altus Biologics; Paragon Healthcare; Intrafusion by McKesson; MPP Infusion Centers; Healix LLC
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
BRAD TRAVERSE Senior Advisor to the Assistant Secretary of Public Affairs (HHS)
Former Senior Advisor, Office of the HHS Assistant Secretary of Public Affairs
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Infusion Providers Alliance had in-house lobbyists. The report was filed on March 22.
Original Filing: 301545432.xml
Lobbying Issues
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
Issues related to down coding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs).
Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act.
of2023 or the PATIENT Act of 2023.
Advocating for access to biosimilars.
HR 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act.
S. 652/HR 2630, Safe Step Act.
S. 1375/HR 830, HELP Copays Act.
Issues related to White Bagging.
Access to Alzheimer's Disease therapies.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Infusion Providers Alliance had in-house lobbyists. The report was filed on Jan. 19.
Original Filing: 301531568.xml
Lobbying Issues
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
Issues related to down coding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs).
Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act.
of2023 or the PATIENT Act of 2023.
Advocating for access to biosimilars.
HR 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act.
S. 652/HR 2630, Safe Step Act.
S. 1375/HR 830, HELP Copays Act.
Issues related to White Bagging.
Access to Alzheimer's Disease therapies.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Infusion Providers Alliance had in-house lobbyists. The report was filed on Sept. 29, 2023.
Original Filing: 301496781.xml
Lobbying Issues
Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 -Inflation Reduction Act of 2022; H.R.8800 - Supporting Medicare Providers Act of 2022; HR 2474, the Strengthening Medicare for Patients and Providers Act; Access and appropriate reimbursement for Part B drugs in clinic setting; support for site neutral payment policies; access to Alzheimer's Disease therapies; Medicare Administrative Contractor coding issues (non-legislative); HR 5391, Protecting Patient Access to Cancer and Complex Therapies Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2691, the Transparent PRICE Act; S 652/HR 2630, Safe Step Act; S 1375/HR 830, HELP Copays Act; H.R. 2679, the PBM Accountability Act; S. 1339, Pharmacy Benefit Manager Reform Act; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 3237, requiring each off-campus outpatient department of a provider to include a unique identifier; H.R. 3285, the Fairness for Patient Medications Act; H.R. 3262, to increase transparency of certain health-related ownership information; S. 1214, the RARE Act; The Lower Costs, More Transparency Act; The Stop Drug Shortages Act; H.R. 4822; Health Care Price Transparency Act of 2023; The Patient Act; Improving Seniors Timely Access to Care Act; The Cutting Copays Act; The Modernizing and Ensuring PBM Accountability Act; The Transparency in Billing Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Infusion Providers Alliance had in-house lobbyists. The report was filed on June 30, 2023.
Original Filing: 301472692.xml
Lobbying Issues
Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 -Inflation Reduction Act of 2022; H.R.8800 - Supporting Medicare Providers Act of 2022; HR 2474, the Strengthening Medicare for Patients and Providers Act; Access and appropriate reimbursement for Part B drugs in clinic setting; support for site neutral payment policies; access to Alzheimer's Disease therapies; Medicare Administrative Contractor coding issues (non-legislative).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2691, the Transparent PRICE Act; S 652/HR 2630, Safe Step Act; S 1375/HR 830, HELP Copays Act; H.R. 2679, the PBM Accountability Act; S. 1339, Pharmacy Benefit Manager Reform Act; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 3237, requiring each off-campus outpatient department of a provider to include a unique identifier; H.R. 3285, the Fairness for Patient Medications Act; H.R. 3262, to increase transparency of certain health-related ownership information; S. 1214, the RARE Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Infusion Providers Alliance had in-house lobbyists. The report was filed on May 3, 2023.
Original Filing: 301469933.xml
Lobbying Issues
Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 -Inflation Reduction Act of 2022; H.R.8800 - Supporting Medicare Providers Act of 2022; HR 2474, the Strengthening Medicare for Patients and Providers Act; Access and appropriate reimbursement for Part B drugs in clinic setting; support for site neutral payment policies; access to Alzheimer's Disease therapies; Medicare Administrative Contractor coding issues (non-legislative).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2691, the Transparent PRICE Act; S 652/HR 2630, Safe Step Act; S 1375/HR 830, HELP Copays Act; H.R. 2679, the PBM Accountability Act; S. 1339, Pharmacy Benefit Manager Reform Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Infusion Providers Alliance had in-house lobbyists. The report was filed on Jan. 24, 2023.
Original Filing: 301444810.xml
Lobbying Issues
Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 -Inflation Reduction Act of 2022; H.R.8800 - Supporting Medicare Providers Act of 2022; H.R. 5376, the Build Back Better Act; Access and appropriate reimbursement for Part B drugs in clinic setting; support for site neutral payment policies; access to Alzheimer's Disease therapies; Medicare Administrative Contractor coding issues (non-legislative).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Infusion Providers Alliance had in-house lobbyists. The report was filed on Oct. 13, 2022.
Original Filing: 301403880.xml
Lobbying Issues
Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 -Inflation Reduction Act of 2022; H.R.8800 - Supporting Medicare Providers Act of 2022; H.R. 5376, the Build Back Better Act; Access and appropriate reimbursement for Part B drugs in clinic setting; support for site neutral payment policies; access to Alzheimer's Disease therapies; Medicare Administrative Contractor coding issues (non-legislative).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Infusion Providers Alliance had in-house lobbyists. The report was filed on July 12, 2022.
Original Filing: 301379341.xml
Lobbying Issues
H.R. 5376, the Build Back Better Act; H.R. 6020, Supporting Medicare Providers Act of 2021; S. 610, Protecting Medicare and American Farmers from Sequester Cuts; Supporting Health Care Providers During the COVID-19 Pandemic Act; H. Rept. 117-130; H.R. 19, The Lower Cost, More Cures Act of 2021; H.R. 3; Access and appropriate reimbursement for Part B drugs in clinic setting; support for site neutral payment policies; access to Alzheimer's Disease therapies; appropriate reimbursement of Medicare Part B drugs; Medicare Administrative Contractor coding issues (non-legislative).
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Infusion Providers Alliance had in-house lobbyists. The report was filed on April 18, 2022.
Original Filing: 301359040.xml
Lobbying Issues
H.R. 5376, the Build Back Better Act; H.R. 6020, Supporting Medicare Providers Act of 2021; S. 610, Protecting Medicare and American Farmers from Sequester Cuts; Supporting Health Care Providers During the COVID-19 Pandemic Act; H. Rept. 117-130; H.R. 19, The Lower Cost, More Cures Act of 2021; H.R. 3; Access and appropriate reimbursement for Part B drugs in clinic setting; support for site neutral payment policies; access to Alzheimer's Disease therapies; appropriate reimbursement of Medicare Part B drugs.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Infusion Providers Alliance had in-house lobbyists. The report was filed on Jan. 20, 2022.
Original Filing: 301336652.xml
Lobbying Issues
H.R. 5376, the Build Back Better Act; H.R. 6020, Supporting Medicare Providers Act of 2021; S. 610, Protecting Medicare and American Farmers from Sequester Cuts; Supporting Health Care Providers During the COVID-19 Pandemic Act; H. Rept. 117-130; H.R. 3; Access and appropriate reimbursement for Part B drugs in clinic setting.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Infusion Providers Alliance had in-house lobbyists. The report was filed on Oct. 21, 2021.
Original Filing: 301315432.xml
Lobbying Issues
Access and appropriate reimbursement for Part B drugs in clinic setting; H. Rept. 117-130; H.R. 3.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
Infusion Providers Alliance filed a lobbying registration on Oct. 19, 2021 for in-house lobbying efforts, effective Aug. 31, 2021.
Original Filing: 301304005.xml
Issue(s) they said they’d lobby about: Access and appropriate reimbursement of Part B drugs in clinic setting; H. Rept. 117-130; H.R. 3. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...